Severe Hypertriglyceridemia Market Size in the 7MM was ~USD 1400 Million in 2023, it is projected to grow at a significant CAGR 2034, estimates DelveInsight

DelveInsight's "Severe Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Severe Hypertriglyceridemia, historical and forecasted epidemiology, as well as the Severe Hypertriglyceridemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Severe Hypertriglyceridemia Market with DelveInsight's In-Depth Report @ Severe Hypertriglyceridemia Market Size- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Severe Hypertriglyceridemia Market Report
• On December 15, 2025- Arrowhead Pharmaceuticals initiated a study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study.
• On December 01, 2025- Ionis Pharmaceuticals Inc. conducted a study of approximately 800 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen during the 157-week treatment period. The study will include a 31-day qualification Period, a 157-week treatment period, and a 13-week post-treatment period.
• The total number of Severe Hypertriglyceridemia diagnosed prevalent cases in the 7MM was nearly 3.6 million cases in 2023 and is projected to increase during the forecast period.
• In 2023, the Severe Hypertriglyceridemia diagnosed prevalent cases were highest in the US among the 7MM, with 2.7 million cases.
• Among EU4 and the UK, the highest number of cases of SHTG was found in Germany whereas Spain accounted for the lowest cases in 2023.
• A significant portion of Severe Hypertriglyceridemia patients remain undiagnosed. Among those who are diagnosed, approximately 50% do not receive treatment. This highlights a major gap in both diagnosis and management of the condition.
• Among the type-specific cases, the number of secondary SHTG cases was higher than that of primary SHTG.
• The leading Severe Hypertriglyceridemia Companies such as Amarin Corporation, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, 89bio, NorthSea Therapeutics B.V., MediciNova, and others.
• Promising Severe Hypertriglyceridemia Therapies such as Plozasiran, Olezarsen, DR10624 Injection, ARO-APOC3, Pegozafermin, Omefas, K-877, Fenofibrate and others.

Stay ahead in the Severe Hypertriglyceridemia Therapeutics Market with DelveInsight's Strategic Report @ Severe Hypertriglyceridemia Market Outlook- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Hypertriglyceridemia Epidemiology Segmentation in the 7MM
• Total Severe Hypertriglyceridemia Diagnosed Prevalent Cases
• Severe Hypertriglyceridemia Type-specific Diagnosed Prevalent Cases
• Severe Hypertriglyceridemia Treatable Cases

Download the report to understand which factors are driving Severe Hypertriglyceridemia epidemiology trends @ Severe Hypertriglyceridemia Prevalence- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Hypertriglyceridemia Marketed Drugs
• VASCEPA/VAZKEPA: Amarin Corporation
VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an orally administered adjunct to diet to reduce TG levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia. It is the first and only FDA-approved medication for reducing cardiovascular risk beyond cholesterol-lowering therapy in high-risk patients approved for treatment. In July 2012, VASCEPA was approved by the US FDA for the reduction of triglyceride levels in patients with =500 mg/dL. In March 2021, marketing authorization was granted to icosapent ethyl in the European Union to reduce the risk of cardiovascular events in patients at high cardiovascular risk under the brand name VAZKEPA. In the same year, the company launched VAZKEPA in Germany.

Severe Hypertriglyceridemia Emerging Drugs
• Olezarsen: Ionis Pharmaceuticals
Olezarsen is an RNA-targeted investigational LIgand Conjugated Antisense (LICA) medicine being evaluated for people at risk of disease due to elevated triglyceride levels, including those with FCS and SHTG. Currently, it is being investigated in Phase III for SHTG. As of October 2024, Ionis Pharmaceuticals expects to release Phase III data for olezarsen in 2025 and the company also anticipates its potential US approval for its use in treating SHTG between 2026 and 2027.

• Plozasiran: Arrowhead Pharmaceuticals
Plozasiran (formerly ARO-APOC3) is designed to reduce the production of the protein ApoC-III through the natural RNA interference (RNAi) mechanism. Currently, the drug is investigated in Phase III. Arrowhead Pharmaceuticals is working on initiating SHASTA-5, a Phase III study in patients with SHTG who are at high risk of acute pancreatitis. According to the August 2024 presentation, Arrowhead Pharmaceuticals is expecting commercialization with growth for plozasiran for SHTG in 2027.

Get In-Depth Knowledge on Severe Hypertriglyceridemia Market Trends and Forecasts with DelveInsight @ Severe Hypertriglyceridemia Treatment Market- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Hypertriglyceridemia Companies
Amarin Corporation, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, 89bio, NorthSea Therapeutics B.V., MediciNova, and others.

Severe Hypertriglyceridemia Market Outlook
SHTG remains challenging to manage, with traditional treatments showing limited success in significantly lowering triglyceride levels or reducing the risk of acute pancreatitis, the most severe complication of SHTG. While dietary intervention is fundamental in treating primary hypertriglyceridemia, it often fails to achieve triglyceride levels below 500 mg/dl, the threshold for AP prevention. Conventional pharmacologic options-such as statins, fibrates, niacin, and omega-3 fatty acids-provide only modest reductions in triglyceride levels and lack compelling evidence of AP prevention. These treatments require a functional lipolytic pathway, making them less effective in Familial Chylomicronemia Syndrome (FCS), where this pathway is absent. This underscores a significant unmet need in the Severe Hypertriglyceridemia Therapeutics Market for more effective therapies that can target both triglyceride reduction and AP prevention.

Severe Hypertriglyceridemia Treatment Market
The existing Severe Hypertriglyceridemia treatment mainly includes different classes of drugs for treating SHTG. These classes' are statins, fibrates, omega-3 fatty acids, and niacin. Currently, Statins lead the SHTG market, followed by fibrates, niacin and omega-3 fatty acids. Despite the availability of treatments like statins, fibrates, and omega-3 fatty acids, SHTG continues to significantly impact patients' quality of life, underscoring a significant unmet need in current therapies.

Unlock Strategic Insights with DelveInsight's Comprehensive Severe Hypertriglyceridemia Market Report @ Severe Hypertriglyceridemia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Severe Hypertriglyceridemia Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Severe Hypertriglyceridemia Companies- Amarin Corporation, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, 89bio, NorthSea Therapeutics B.V., MediciNova, and others.
• Severe Hypertriglyceridemia Therapies-
• Severe Hypertriglyceridemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Severe Hypertriglyceridemia Unmet Needs, KOL's views, Analyst's views, Severe Hypertriglyceridemia Market Access and Reimbursement

Table of Content
1: Key Insights
2: Severe Hypertriglyceridemia Market Report Introduction
3: Severe Hypertriglyceridemia Market Overview at a Glance
4: Severe Hypertriglyceridemia Epidemiology and Market Methodology
5: Severe Hypertriglyceridemia Executive Summary
6: Key Events
7: Severe Hypertriglyceridemia Background and Overview
8: Severe Hypertriglyceridemia Epidemiology and Patient Population
9: Severe Hypertriglyceridemia Patient Journey
10: Severe Hypertriglyceridemia Marketed drugs
11: Severe Hypertriglyceridemia Emerging Drugs
12. Key Cross Competition
13: Severe Hypertriglyceridemia Unmet Needs
14: Severe Hypertriglyceridemia SWOT Analysis
15: Key Opinion Leaders' Views
16: Reimbursement and Market Access
17: Appendix
18: DelveInsight Capabilities
19: Disclaimer
20: About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.